2012-09-17 06:00:56 - Recently published research from Global Markets Direct, "Encephalitis - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Encephalitis - Pipeline Review, H2 2012', provides an overview of the Encephalitis therapeutic pipeline. This report provides information on the therapeutic development for Encephalitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Encephalitis. 'Encephalitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot

of the global therapeutic scenario for Encephalitis.
* A review of the Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Encephalitis pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/463741_encephalitis_pipeline_review_h2_2012. ..


Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Encephalitis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Encephalitis pipeline depth and focus of Encephalitis therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Encephalitis Therapeutic Products under Development, Key Players in Encephalitis Therapeutics, Encephalitis Pipeline Overview, Encephalitis Pipeline, Encephalitis Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Encephalitis Overview
Therapeutics Development
An Overview of Pipeline Products for Encephalitis
Encephalitis Therapeutics under Development by Companies
Encephalitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Encephalitis Therapeutics - Products under Development by Companies
Encephalitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Encephalitis Therapeutics Development
Sanofi-Aventis
CEL-SCI Corporation
CytoGenix, Inc.
Boryung Pharmaceutical Co., Ltd.
Panacea Biotec Limited
Clavis Pharma ASA
AlphaVax, Inc.
Sinovac Biotech Ltd.
NasVax Ltd.
Vaxine Pty Ltd
Encephalitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
DNA Vaccine For Viral Infection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Equine Encephalitis Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CST-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CP-4018 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
20% Diethyltoluamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Japanese Encephalitis SA 14-14-2 Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FSME-IMMUN - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Western Equine Encephalitis Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imojev - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VEE TC-83 - Drug Profile
Product Description
Mechanism of Action

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463741&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.